Related Experiment Video
Updated: May 25, 2026
07:10
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
The Antibody Response against HIV-1
1Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Cold Spring Harbor Perspectives in Medicine
|February 9, 2012
Summary
Neutralizing antibodies (NAbs) are crucial for controlling viral infections and vaccine efficacy. For HIV-1, NAbs drive viral evolution and face challenges from viral diversity, limiting their control during infection.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- Neutralizing antibodies (NAbs) are vital for controlling viral infections and are key components of successful vaccines.
- While animal models show NAbs can prevent HIV-1 acquisition, their role in human HIV-1 infection and control is limited.
- HIV-1-specific NAbs drive the evolution of the virus's envelope glycoprotein within infected individuals.
Purpose of the Study:
- To investigate the role of neutralizing antibodies in HIV-1 infection and vaccine design.
- To understand the challenges posed by HIV-1's antigenic diversity to antibody-mediated control.
- To explore antibody effector functions beyond neutralization in controlling HIV-1.
Main Methods:
- Analysis of experimental animal models and human data on neutralizing antibody activity against HIV-1.
- Investigation of HIV-1 envelope glycoprotein evolution driven by immune selection.
- Identification and characterization of novel potent monoclonal antibodies (MAbs) targeting conserved HIV-1 epitopes.
- Exploration of antibody-dependent cell-mediated cytotoxicity (ADCC) in HIV-1 control.
Main Results:
- HIV-1's ability to evade immune selection is a primary reason for limited NAb control during infection.
- The extraordinary antigenic diversity of HIV-1 presents a significant challenge for developing broadly protective NAbs.
- New potent MAbs are revealing common epitopes across diverse HIV-1 strains.
- Antibodies may control HIV-1 replication through effector functions, such as killing infected cells.
Conclusions:
- Understanding antibody impact on HIV-1 transmission and pathogenesis is critical for rational HIV-1 vaccine design.
- Targeting conserved epitopes and exploring combined antibody mechanisms (neutralization and effector functions) may enhance vaccine efficacy.
- Further research into NAbs and antibody effector functions is essential for advancing HIV-1 prevention and treatment strategies.
Related Concept Videos
01:29Immune Response Against Viral Pathogens
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
00:42Cross-reactivity
Overview
01:36Humoral Immune Responses
Overview
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...